Do analysts prefer RGC or RDY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, RGC or RDY?

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Dr. Reddy's Laboratories $3.58B 2.84 $456M $0.44 27.66

Which has stronger earnings & valuation, CRNX or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crinetics Pharmaceuticals $7.70M 1,168.70 -$465.32M -$5.04 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Do analysts recommend LQDA or RGC?

Liquidia presently has a consensus target price of $98.08, indicating a potential upside of 44.90%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liquidia 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.45 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, LQDA or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 38.27 -$68.92M $1.37 49.41 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Do analysts rate RGC or LNTH?

Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.29%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantheus 0 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29

Which has higher earnings & valuation, RGC or LNTH?

Lantheus has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.34

Do analysts rate RGC or BLTE?

Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 35.64%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Belite Bio 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has preferable earnings and valuation, RGC or BLTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is RGC or BLTE more profitable?

Regencell Bioscience's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Belite Bio N/A -11.84% -11.62%

Regencell Bioscience (RGC) Competitors

$5.50 -0.02 (-0.36%)

As of 08/28/2026 04:00 PM Eastern

Compare

RGC vs. RDY, CRNX, LQDA, LNTH, and BLTE

Should you buy Regencell Bioscience stock or one of its competitors? Regencell Bioscience's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Liquidia (LQDA), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Regencell Bioscience (NASDAQ:RGC) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Regencell Bioscience's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.66

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Very Positive
Dr. Reddy's Laboratories	Positive

Summary

Dr. Reddy's Laboratories beats Regencell Bioscience on 8 of the 10 factors compared between the two stocks.

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Regencell Bioscience's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Regencell Bioscience	N/A	N/A	N/A

Regencell Bioscience has lower revenue, but higher earnings than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Crinetics Pharmaceuticals had 9 more articles in the media than Regencell Bioscience. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Crinetics Pharmaceuticals' score of 1.56 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Very Positive
Regencell Bioscience	Very Positive

Crinetics Pharmaceuticals presently has a consensus price target of $81.00, indicating a potential downside of 4.53%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Crinetics Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Crinetics Pharmaceuticals beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

In the previous week, Liquidia had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Liquidia and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Liquidia's score of 0.88 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Liquidia	Positive
Regencell Bioscience	Very Positive

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Liquidia has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Regencell Bioscience's net margin of 0.00%. Liquidia's return on equity of 149.65% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Regencell Bioscience	N/A	N/A	N/A

Regencell Bioscience has lower revenue, but higher earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.27	-$68.92M	$1.37	49.41
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Liquidia presently has a consensus target price of $98.08, indicating a potential upside of 44.90%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Liquidia beats Regencell Bioscience on 11 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Lantheus?

Regencell Bioscience (NASDAQ:RGC) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.29%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has a net margin of 17.69% compared to Regencell Bioscience's net margin of 0.00%. Lantheus' return on equity of 28.10% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Lantheus	17.69%	28.10%	14.35%

Lantheus has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.34

Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 8 more articles in the media than Regencell Bioscience. MarketBeat recorded 9 mentions for Lantheus and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Lantheus' score of 1.37 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Very Positive
Lantheus	Positive

Summary

Lantheus beats Regencell Bioscience on 10 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Belite Bio?

Regencell Bioscience (NASDAQ:RGC) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Regencell Bioscience's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Belite Bio	N/A	-11.84%	-11.62%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 35.64%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Belite Bio had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Belite Bio and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Belite Bio's score of 0.93 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Very Positive
Belite Bio	Positive

Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Belite Bio beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGC vs. The Competition

Export

Metric	Regencell Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.72B	$12.17B	$7.23B	$12.95B
Dividend Yield	N/A	2.62%	2.54%	11.02%
P/E Ratio	N/A	787.65	273.45	25.45
Price / Sales	N/A	763.23	624.60	95.63
Price / Cash	N/A	95.73	79.29	54.21
Price / Book	550.00	11.97	12.97	6.14
Net Income	-$3.58M	$2.83B	$3.48B	$348.86M
7 Day Performance	3.77%	0.40%	0.13%	-0.80%
1 Month Performance	-2.65%	6.25%	8.37%	5.56%
1 Year Performance	-60.85%	5.95%	24.55%	15.57%

Regencell Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGC Regencell Bioscience	0.2518 of 5 stars	$5.50 -0.4%	N/A	-64.0%	$2.72B	N/A	N/A	10	Positive News
RDY Dr. Reddy's Laboratories	1.7864 of 5 stars	$12.11 -0.4%	N/A	-14.5%	$10.14B	$3.58B	27.51	27,527	News Coverage Analyst Upgrade
CRNX Crinetics Pharmaceuticals	1.6775 of 5 stars	$84.69 0.0%	$81.00 -4.4%	+176.8%	$8.99B	$7.70M	N/A	210	Positive News
LQDA Liquidia	4.2092 of 5 stars	$75.33 +1.3%	$98.08 +30.2%	+146.5%	$6.65B	$158.32M	54.99	50	Insider Trade
LNTH Lantheus	3.9666 of 5 stars	$100.48 +0.2%	$108.11 +7.6%	+81.6%	$6.54B	$1.54B	24.27	1,193	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regencell Bioscience (RGC) Competitors

RGC vs. RDY, CRNX, LQDA, LNTH, and BLTE

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Summary

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Summary

How does Regencell Bioscience compare to Liquidia?

Summary

How does Regencell Bioscience compare to Lantheus?

Summary

How does Regencell Bioscience compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regencell Bioscience (RGC) Competitors

RGC vs. RDY, CRNX, LQDA, LNTH, and BLTE

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Is RGC or RDY more profitable?

Do analysts prefer RGC or RDY?

Do institutionals and insiders have more ownership in RGC or RDY?

Which has more volatility & risk, RGC or RDY?

Which has preferable valuation and earnings, RGC or RDY?

Does the media favor RGC or RDY?

Summary

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Which has more volatility and risk, CRNX or RGC?

Is CRNX or RGC more profitable?

Which has stronger earnings & valuation, CRNX or RGC?

Does the media favor CRNX or RGC?

Do analysts prefer CRNX or RGC?

Do institutionals & insiders have more ownership in CRNX or RGC?

Summary

How does Regencell Bioscience compare to Liquidia?

Does the media refer more to LQDA or RGC?

Do insiders & institutionals have more ownership in LQDA or RGC?

Which has more risk and volatility, LQDA or RGC?

Is LQDA or RGC more profitable?

Which has higher earnings & valuation, LQDA or RGC?

Do analysts recommend LQDA or RGC?

Summary

How does Regencell Bioscience compare to Lantheus?

Do insiders & institutionals believe in RGC or LNTH?

Do analysts rate RGC or LNTH?

Is RGC or LNTH more profitable?

Which has higher earnings & valuation, RGC or LNTH?

Which has more risk and volatility, RGC or LNTH?

Does the media refer more to RGC or LNTH?

Summary

How does Regencell Bioscience compare to Belite Bio?

Is RGC or BLTE more profitable?

Which has preferable earnings and valuation, RGC or BLTE?

Do analysts rate RGC or BLTE?

Does the media refer more to RGC or BLTE?

Which has more volatility and risk, RGC or BLTE?

Do institutionals and insiders believe in RGC or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools